Answers are grounded in this paper and cite their sources.
Diastolic dysfunction with left ventricular hypertrophy and myocardial fibrosis is an important characteristic of uremic cardiomyopathy in end-stage kidney disease (ESKD). Few studies explored the relationship between changes in diastolic dysfunction and the risk of mortality or cardiovascular outcome in patients with ESKD. We investigated the clinical impact of diastolic dysfunction and atrial fibrillation (AF) on patients starting hemodialysis (HD).
No takes yet. Share an insight, caveat, or question.
Jeon et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: